THIOBUTABARBITAL

Possibly Marketed Outside US

Details

Stereochemistry	UNKNOWN
Molecular Formula	C10H16N2O2S
Molecular Weight	228.311
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC(C)C1(CC)C(=O)NC(=S)NC1=O

InChI

InChIKey=IDELNEDBPWKHGK-UHFFFAOYSA-N

InChI=1S/C10H16N2O2S/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13217426 | https://www.ncbi.nlm.nih.gov/pubmed/13500903 | https://www.ncbi.nlm.nih.gov/pubmed/13991716 | http://www.sciencedirect.com/topics/neuroscience/thiobarbiturates

Thiobutabarbital is a barbiturate derivative invented in the 1950s. It has sedative, anticonvulsant and hypnotic effects, it is used in veterinary medicine for induction in surgical anaesthesia. Thiobutabarbital was formerly used as anesthetic Inactin. ‘Inactin’ (sodium thiobutabarbital) produces smooth induction of anaesthesia after intravenous administration and has a prolonged duration of action. It has variable analgesic activity.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
hexose transport 2 Target ID: GO:0008645 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7819247	Inhibitor 8297		1.0 mM [IC50]
hexose transport 2 Target ID: GO:0008645 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7819247	Inhibitor 8297		1.0 mM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 614 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19881310 https://www.ncbi.nlm.nih.gov/pubmed/13283294 http://www.sciencedirect.com/topics/neuroscience/thiobarbiturates	Primary		Approved 8429	Inactin Approved Use Unknown

PubMed

Title	Date	PubMed
Effects of BW245C, a prostaglandin dp receptor agonist, on systemic and regional haemodynamics in the anaesthetized rat.	2005 Nov	16405449
The effect of brevenal on brevetoxin-induced DNA damage in human lymphocytes.	2005 Nov	15986201
Total synthesis of the proposed structure of brevenal.	2006 Aug 2	16866516
The inhibition of CHO-K1-BH4 cell proliferation and induction of chromosomal aberrations by brevetoxins in vitro.	2006 Jul	16487644
Hemodynamic effects of potent and selective JNK inhibitors in anesthetized rats: implication for targeting protein kinases in metabolic diseases.	2007 Jan 15	17055723
Glucose-induced time-dependent potentiation of insulin release, but not islet blood perfusion, in anesthetized rats.	2008	18521798
Low-dose candesartan improves renal blood flow and kidney oxygen tension in rats with endotoxin-induced acute kidney dysfunction.	2008 Aug	18091574
Brevisamide: an unprecedented monocyclic ether alkaloid from the dinoflagellate Karenia brevis that provides a potential model for ladder-frame initiation.	2008 Aug 21	18646771
Resistin increases islet blood flow and decreases subcutaneous adipose tissue blood flow in anaesthetized rats.	2009 Feb	18715288

Patents

Sample Use Guides

In Vivo Use Guide

Male Wistar rats (8 to 10 weeks old) were anesthetized with thiobutabarbital (120 mg/kg, intraperitoneally (i.p.)).

Route of Administration: Intraperitoneal

In Vitro Use Guide

Thiobutabarbital inhibits hexose transport in cultured 3T3-C2 cells with IC50 value of 1.0 mM.

Name

Type

Language

THIOBUTABARBITAL

Common Name

English

5-ETHYL-5-(1-METHYLPROPYL)-2-THIOBARBITURIC ACID

Systematic Name

English

Thiobutabarbital [WHO-DD]

Common Name

English

5-SEC-BUTYL-5-ETHYL-2-THIOXODIHYDROPYRIMIDINE-4,6(1H,5H)-DIONE

Systematic Name

English

THIOBUTABARBITAL [MI]

Common Name

English

NSC-32372

Code

English

5-ETHYLDIHYDRO-5-(1-METHYLPROPYL)-2-THIOXO-4,6(1H,5H)-PYRIMIDINEDIONE

Systematic Name

English

5-SEC-BUTYL-5-ETHYL-2-THIOBARBITURIC ACID

Systematic Name

English

THIOBUTABARBITAL [VANDF]

Common Name

English

THIBUTABARBITAL

Common Name

English

NSC-27685

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C67084